

**Fig. S1.** Timeline of experimental procedures and behavioral tests. Each of the three horizontal lines is one of three birds tested on the same day. Blue indicates the food deprivation period, and red indicates the test of competition over food. The yellow line indicates time of injection.



**Fig. S2**. Cage used for behavioural tests, identical to the home cages and located side-by-side with them. The test cage contained four perches in symmetrical positions, similarly to the home cages, plus two feeders, one placed next to the rightmost perch, and the other next to the leftmost perch.

**Table S1**. Distribution of treatments (control, D2R agonist and D2R antagonist) across the 11 experimental birds. Different tests to the same bird treatments were separated in time by seven days. Experiments took place during mornings, between 09:00 am and 12:30 pm, from the 22nd July to the 5th September 2019.

Round	Day	Cage	Sex	Bird tested	Companion bird	Treatment
1	1	1	Male	24B	117A	D2 Agonist
		5	Female	118A		D2 Antagonist
		3	Male	34P	26B	Control
	2	4	Female	32P		D2 Agonist
		2	Male	122AB	123A	D2 Antagonist
		6	Female			
	3	1	Female	28P	13V	D2 Agonist
		5	Male	113AB		D2 Antagonist
		3	Female	31A	4V	Control
	4	4	Male	116A		D2 Agonist
		2	Female	35P	30V	D2 Antagonist
		6	Male	115A		Control
2		1	Male	24B		D2 Antagonist
	1	5	Female	118A	14V	Control
		3	Male	34P		D2 Agonist
	2	4	Female	32P	17V	D2 Antagonist
		2	Male	122AB		Control
		6	Female		37B	
	3	1	Female	28P		D2 Antagonist
		5	Male	113AB	38P	Control
		3	Female	31A		D2 Agonist
	4	4	Male	116A	27B	D2 Antagonist
		2	Female	35P		Control
		6	Male	115A	11P	D2 Agonist

Table S1. (continued)

Round	Day	Cage	Sex	Bird tested	Companion bird	Treatment
	1	1	Male	24B	117A	Control
		5	Female	118A		D2 Agonist
		3	Male	34P	26B	D2 Antagonist
	2	4	Female	32P		Control
3		2	Male	122AB	123A	D2 Agonist
		6	Female			
		1	Female	28P	13V	Control
	3	5	Male	113AB		D2 Agonist
		3	Female	31A	4V	D2 Antagonist
	4	4	Male	116A		Control
		2	Female	35P	30V	D2 Agonist
		6	Male	115A		D2 Antagonist
	1	1	Male	24B		D2 Agonist
		5	Female	118A	14V	D2 Antagonist
		3	Male	34P		Control
		4	Female	32P	17V	D2 Agonist
	2	2	Male	122AB		D2 Antagonist
4		6	Female		37B	
		1	Female	28P		D2 Agonist
	3	5	Male	113AB	38P	D2 Antagonist
		3	Female	31A		Control
	4	4	Male	116A	27B	D2 Agonist
		2	Female	35P		D2 Antagonist
		6	Male	115A	11P	Control
	1	1	Male	24B	117A	D2 Antagonist
		5	Female	118A		Control
		3	Male	34P	26B	D2 Agonist
	2	4	Female	32P		D2 Antagonist
		2	Male	122AB	123A	Control
5		6	Female			
	3	1	Female	28P	13V	D2 Antagonist
		5	Male	113AB		Control
		3	Female	31A	4V	D2 Agonist
	4	4	Male	116A		D2 Antagonist
		2	Female	35P	30V	Control
		6	Male	115A		D2 Agonist
	1	1	Male	24B	4.47.7	Control
		5	Female	118A	14V	D2 Agonist
		3	Male	34P	4.57.7	D2 Antagonist
	2	4	Female	32P	17V	Control
		2	Male	122AB	250	D2 Agonist
6		6	Female	200	37B	0 1
	3	1	Female	28P	200	Control
		5	Male	113AB	38P	D2 Agonist
		3	Female	31A	270	D2 Antagonist
	4	4	Male	116A	27B	Control
		2	Female	35P	110	D2 Agonist
		6	Male	115A	11P	D2 Antagonist

**Table S2.** GLMM contrasts between behavior (activity or aggressiveness) in control conditions and following each of the dopaminergic manipulations, separately for females and males. The reference level for the factor treatment is the "control" and comparison levels are D2 agonist and D2 antagonist, and for the factor social context the reference level is "alone" and the comparison level is "with companion", n = 11.

	Estimate	Z value (P)	Estimate	Z value (P)
	Activity Females		Activity Males	
Contrasts with control treatment:				
D2 Agonist	-1.11	-2.47 ( <b>0.01</b> )	0.31	0.55 (0.58)
D2 Antagonist	-0.12	-0.27 (0.79)	0.60	1.06 (0.29)
Contrast with the alone social treatment:				
With companion	-0.10	-0.23 (0.82)	0.04	0.06 (0.95)
2-way interactions with DAergic treatment:				
D2 Agonist x with companion	0.16	0.25 (0.80)	0.16	0.20 (0.84)
D2 Antagonist x with companion	-0.52	-0.82 (0.41)	0.34	0.43 (0.67)
	Aggressiveness Females		Aggressiveness Males	
Contrasts with control treatment:				
D2 Agonist	-0.98	-1.45 (0.15)	-1.39	-1.75 (0.08)
D2 Antagonist	0.49	1.08 (0.28)	-1.39	-1.75 (0.08)